All trading involves risk. Ensure you understand those risks before trading.
All trading involves risk. Ensure you understand those risks before trading.

Risk Appetite Explodes on 90 Effective COVID19 Vaccine

Article By: ,  Head of Market Research

Risk Appetite EXPLODES on 90% Effective COVID-19 Vaccine

Hallelujah!

In results that the CEO of Pfizer hailed as a “great day for science and humanity,” the company announced that its COVID-19 vaccine was found to be more than 90% effective in Phase 3 trials. This efficacy exceeds most scientists wildest dreams; previously NIH Director Anthony Fauci had said that a 50-60% effective vaccine would be “acceptable” and most scientists were hoping for something in the 70% range. The study included over 43,000 participants.

Moving forward, Pfizer and vaccine co-creator BioNTech have indicated that they plan to apply for emergency use authorization from the US FDA in two weeks’ time. Assuming no setbacks, the firms expect to produce 50 million doses of the vaccine in 2020 and 1.3 billion doses in 2021, raising hopes of a potential “return to normal” in the middle of next year for much of the developed world.

Market Reaction

Combined with the resolution of the US election this weekend, traders have multiple reasons for optimism as the week kicks off. That said, the market moves aren’t necessarily a one-way street. While futures on the more “old world” S&P 500 and Dow Jones Industrial Average indices are surging 4-5% ahead of the open, the technology-heavy Nasdaq is actually poised to open marginally lower on the day. Many of the massive technology behemoths (think Apple, Amazon, Facebook, Netflix, Alphabet/Google, and Microsoft) as well as smaller stay-at-home centric rivals (Zoom Video, Fastly, Peloton, Shopify, Nvidia, etc) will now face a much tougher competitive landscape sooner than expected. To wit, futures on the small-cap focused Russell 2000 index are trading “limit up” (+7%), meaning that the index can’t advance further until markets officially open.

Source: TradingView, GAIN Capital

Outside of equities, the reaction is a bit more intuitive. In the FX market, growth-sensitive currencies like the “commodity dollars” (AUD, NZD, and CAD) are surging along with emerging market currencies, while traditional safe havens like the JPY, CHF, and USD are lagging. Likewise, gold is trading down by nearly 4% while WTI cruide oil is up by nearly 10%(!). Finally, the yield on the benchmark 10-year US Treasury bond is trading up 11bps to 0.92%, signaling optimism and risk appetite across the globe.


Source: TradingView, GAIN Capital

While the hard-working scientists at Pfizer and BioNTech are still putting the finishing touches on their research, traders are buying first and asking questions later. In the words of Pfizer CEO Albert Bourla, “We can see the light at the end of the [COVID-19 pandemic] tunnel”, and not a moment too soon with global infection rates setting new records, hospitals nearing capacity, and economies struggling to reopen.


From time to time, StoneX Financial Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.

City Index is a trading name of StoneX Financial Pty Ltd.

The material provided herein is general in nature and does not take into account your objectives, financial situation or needs.

While every care has been taken in preparing this material, we do not provide any representation or warranty (express or implied) with respect to its completeness or accuracy. This is not an invitation or an offer to invest nor is it a recommendation to buy or sell investments.

StoneX recommends you to seek independent financial and legal advice before making any financial investment decision. Trading CFDs and FX on margin carries a higher level of risk, and may not be suitable for all investors. The possibility exists that you could lose more than your initial investment further CFD investors do not own or have any rights to the underlying assets.

It is important you consider our Financial Services Guide and Product Disclosure Statement (PDS) available at www.cityindex.com/en-au/terms-and-policies/, before deciding to acquire or hold our products. As a part of our market risk management, we may take the opposite side of your trade. Our Target Market Determination (TMD) is also available at www.cityindex.com/en-au/terms-and-policies/.

StoneX Financial Pty Ltd, Suite 28.01, 264 George Street, Sydney, NSW 2000 (ACN 141 774 727, AFSL 345646) is the CFD issuer and our products are traded off exchange.

© City Index 2024